Utidelone vs docetaxel for HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman age 18 or older and be able to sign consent.
- Your breast cancer must be locally advanced or metastatic, and tests must confirm it is HER2-negative (not HER2-positive).
- Your health should be fairly good for treatment (ECOG 0–1).
- You need at least one spot that doctors can measure on scans, or bone-only spread that can be checked with bone scan, PET, or MRI.
- If you’ve had chemo with a taxane before, it must have been for earlier-stage breast cancer and finished at least 12 months before starting this study; you should not have had chemo for advanced breast cancer before.
- You must have recovered from past treatment side effects to mild levels (grade 1 or less), and you need adequate blood, liver, and kidney function.
- If you can become pregnant, you must use birth control during treatment and for at least 90 days after the last dose; you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study compares two chemotherapy combinations to treat HER2-negative breast cancer that has spread or is locally advanced. It aims to find which plan works better and has an acceptable side-effect profile for people who have had prior taxane treatment (in earlier-stage settings).
This study tests if a new form of the drug Utidelone (given as a capsule) works as well as the current injection for people with HER2-negative advanced breast cancer. It may be an option if you have already had chemotherapy and your cancer is still growing.
This trial tests a combination of two chemotherapy drugs, utidelone and capecitabine, for women with HER2-negative breast cancer that has spread to other parts of the body. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
This trial tests a chemotherapy drug called utidelone given before surgery to shrink high-risk or locally advanced breast cancer. It may help make surgery more effective.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.